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Vitamin-K antagonists (VKAs) present an effective anticoagulant treatment in deep venous
thrombosis (DVT). However, the use of VKAs is limited because of the risk of bleeding and
the necessity of frequent and long-term laboratory monitoring. Therefore, new oral anticoag-
ulant drugs (NOACs) such as dabigatran, with lower rates of (major) intracranial bleeding
compared to VKAs and not requiring monitoring, may be considered.
Objectives
To estimate resource utilization and costs of patients treated with the VKAs acenocoumarol
and phenprocoumon, for the indication DVT. Furthermore, a formal cost-effectiveness anal-
ysis of dabigatran compared to VKAs for DVT treatment was performed, using these
estimates.
Methods
A retrospective observational study design in the thrombotic service of a teaching hospital
(Deventer, The Netherlands) was applied to estimate real-world resource utilization and
costs of VKA monitoring. A pooled analysis of data from RE-COVER and RE-COVER II on
DVT was used to reflect the probabilities for events in the cost-effectiveness model. Dutch
costs, utilities and specific data on coagulation monitoring levels were incorporated in the
model. Next to the base case analysis, univariate probabilistic sensitivity and scenario anal-
yses were performed.
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Results
Real-world resource utilization in the thrombotic service of patients treated with VKA for the
indication of DVT consisted of 12.3 measurements of the international normalized ratio
(INR), with corresponding INR monitoring costs of €138 for a standardized treatment period
of 180 days. In the base case, dabigatran treatment compared to VKAs in a cohort of 1,000
DVT patients resulted in savings of €18,900 (95% uncertainty interval (UI) -95,832,
151,162) and 41 (95% UI -18, 97) quality-adjusted life-years (QALYs) gained calculated
from societal perspective. The probability that dabigatran is cost-effective at a conservative
willingness-to pay threshold of €20,000 per QALY was 99%. Sensitivity and scenario analy-
ses also indicated cost savings or cost-effectiveness below this same threshold.
Conclusions
Total INR monitoring costs per patient were estimated at minimally €138. Inserting these
real-world data into a cost-effectiveness analysis for patients diagnosed with DVT, dabiga-
tran appeared to be a cost-saving alternative to VKAs in the Netherlands in the base case.
Cost savings or favorable cost-effectiveness were robust in sensitivity and scenario analy-
ses. Our results warrant confirmation in other settings and locations.
Introduction
Deep venous thrombosis (DVT) and pulmonary embolism (PE) together are labelled venous
thromboembolism (VTE), often characterized by severe disability and impairment of quality of
life [1]. Accurate anticoagulant therapy for DVT is important to prevent increase of the blood
clot, occurrence of PE, or recurrent DVT [2]. Patients with DVT are recommended to receive
direct working low-molecular-weight heparins (LMWHs) for at least five days combined with
subsequent administration of vitamin K antagonists (VKAs; e.g. warfarin, acenocoumarol or
phenprocoumon) for three to six months [3,4]. In exceptional cases, long-term anticoagulant
treatment prolonged to up to twelve months is preferred [5], but grossly, an averaged half year
of treatment seems a reasonable postulate.
The optimal effectiveness and safety of VKAs is established in a narrow therapeutic range,
with the international normalized ratio (INR) being used internationally as a standardised
measure of VKA’s biologic effect [4,6]. To maintain the dose at adequate levels, frequent and
long-term laboratory monitoring and dose-adjustment is required [5]. Furthermore, VKA
treatment may be complicated with multiple drug and food interactions and with pharmacoge-
netic variability [7,8].
Overcoming some of these disadvantages of VKAs for both the patient and healthcare pro-
vider, new oral anticoagulants (NOACs) have been introduced in the last few years [9].
NOACs can modulate the coagulation cascade without requiring laboratory testing or dose-
adjustments because of a predictable pharmacokinetic profile [10]. They can also be adminis-
tered at a fixed dose and have a rapid onset of action [11].
Dabigatran is a NOAC recently approved by the EMA for the treatment of DVT in Europe
[12,13]. In the RE-COVER and RE-COVER II trials, 6 months of treatment with dabigatran
150 mg (twice daily) after initial parenteral anticoagulation was found non-inferior to dose-
adjusted VKAs in the treatment of DVT with less major, non-major and minor bleedings in
patients using dabigatran [14,15]. Currently, NOACs are not yet included in the Dutch
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Reimbursement System for the DVT indication. For inclusion, a thorough pharmacoeconomic
analysis is one of the requirements set by the Ministry of Health.
The first aim of this study is to estimate resource utilization related to INR monitoring, as
these are yet unknown for DVT treatment in the Dutch setting. This estimate will subsequently
be translated into INR monitoring costs of patients treated with VKAs. Original real-world
data are gathered from the thrombotic service from the Deventer Hospital. Secondly, a cost-
effectiveness analysis of dabigatran compared to VKAs for the indication of DVT will be per-




The study was conducted in accordance with the requirements of the Dutch act on protection
of personal data [16]. Only anonymous data were used. Observational research with data does
not fall within the ambit of the Dutch Act on research involving human subjects and does not
require the approval of an ethics review board. This study conformed to the principles embod-
ied in the Declaration of Helsinki [17].
Real-world data gathered from Deventer Hospital
To estimate resource utilization and translate this into INR monitoring costs, a retrospective
observational study design was used. All patients treated in the year 2013 with VKAs for the
indication of DVT at the thrombotic service from Deventer Hospital (a Dutch teaching hospi-
tal) were enrolled, except those few patients who switched to self-measurement during this
year. The latter and the limitation to DVT was done to achieve a sizeable and homogeneous
DVT-only study population. Indeed, both initial PE and self-measurement were scarce during
our observation period in the Deventer Hospital and sizes would not allow reliable estimates
for these subgroups. From the available 2013 data, the total treatment period and the following
four types of resource utilization were calculated: total of INR measurements, measurements
sampled at the thrombotic service, measurements sampled at home and numbers of required
dose-adjustments. Means and standard deviations (SD) of all types of resource utilization were
calculated. Total resource utilization was divided by total person-years of treatment and subse-
quently standardized to 180 days (in the base case). In addition, resource utilizations were
translated into INR monitoring costs by multiplying INR measurements sampled at the throm-
botic service by €10.37 and multiplying INR measurements sampled at home by €12.77 [18].
Decision model
The retrospective observational study design from Deventer Hospital and data from the pooled
RE-COVER and RE-COVER II trials were used as the basis to calculate the cost-effectiveness
of dabigatran compared to VKAs as anticoagulant therapy for the indication DVT [19]. The
trials were double-blind, double-dummy, randomized trials, comparing 6 months of treatment
with dabigatran at a fixed dose of 150 mg twice daily (dabigatran arm) with 6 months of dose-
adjusted warfarin therapy (VKA arm), after initial parenteral anticoagulation with LMWHs.
Notably and plausibly, for the purpose of this study warfarin is considered equal to other
VKAs, based on the grossly similar efficacy and safety profiles, with acenocoumarol and phen-
procoumon specifically being used in the Netherlands [20,21].
Following health states were included in the model: symptomatic (recurrent) DVT and
symptomatic non-fatal PE, major bleedings, clinically relevant non-major bleedings and minor
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bleeding events (Fig 1) [22]. To consistently apply conservative assumptions for dabigatran,
potential benefits of dabigatran treatment on deaths related to VTE were excluded in this
study. Notably, due to the short time horizon of the model, all-cause mortality was also
neglected. Relevant probabilities were calculated from corresponding data derived from the
pooled RE-COVER and RE-COVER II trials (S1 Table)[19]. Probabilities of patients being in a
particular health state were calculated for a treatment period of six months, corresponding to
180 days anticoagulation therapy in the base case. In the base case all differences were evalu-
ated, including all their respective uncertainties within a probabilistic sensitivity analysis.
Utilities
For every health state and event derived from data from the pooled RE-COVER and
RE-COVER II trials, utilities were determined. Utilities represent preferences for a given health
state scaled from 0 to 1, where 0 represents death and 1 represents perfect health [23]. Utilities
were derived from the literature (S2 Table) [13,24–26] and corrected for the age-specific utility
of the specific population targeted (on average 55 year according to the clinical trials) and for
the duration in the following way:










Fig 1. Decisionmodel for the DVT population. The model starts with the diagnosis deep venous thrombosis. All patients directly started with the treatment
of VKA or dabigatran anticoagulation, probabilities for events differ per arm. VTE: venous thromboembolism; DVT: deep venous thrombosis; PE: pulmonary
embolism; CRNM: clinically relevant non-major.
doi:10.1371/journal.pone.0135054.g001
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UHSP = Utility of a speciﬁc health state corrected for the overall age-speciﬁc utility of the popu-
lation concernedUHS = Utility of a speciﬁc health stateUP = Age-speciﬁc utility of the overall
population concernedTDHS = Total duration of speciﬁc health state within the total treatment
period of 180 daysTU = Total utility in model during 180 days for a 55-year old DVT-patient
These formulas were applied to each health state (HS) and subsequently summed over all
patients in the cohort. Total utility (TU) was interpreted as reflecting the quality adjusted life
years (QALYs; duration times utility). QALYs were estimated for the intervention of dabiga-
tran and for the comparator of VKAs. Taking the difference resulted in QALYs gained, which
was subsequently inserted in the denominator of the cost-effectiveness ratio (see below).
Costs
Prices of dabigatran, defined as price per defined daily dose (2x 150 mg) and VKAs were taken
from the official Dutch price list (Z-index). Costs of VKA treatment was estimated as a
weighted average cost of acenocoumarol and phenprocumon based on their use in the Nether-
lands (80%:20% respectively) [27,28]. Costs associated with clinical events (VTE, recurrent
DVT, PE and major bleeding) were based on actual costs or standard unit costs from the
Dutch Cost Manual [29,30]. Minor bleeding costs were estimated as equalling the costs of a
general practitioner’s visit and clinical relevant non-major bleeding costs were derived from
minor bleeding costs with productivity losses’ costs added [18,31]. INR monitoring costs gath-
ered from data of the thrombotic service of Deventer Hospital were added to the VKA treat-
ment costs, as well as traveling costs and costs due to productivity losses. All prices were
expressed in €’s, adjusted to reflect 180 days of treatment and updated to 2013 using the Dutch
inflation index (S3 Table) [18,29,31,32].
Cost-effectiveness analysis
The incremental cost-effectiveness ratio (ICER) was defined as the additional costs of the more
expensive treatment divided by its added clinical benefit in QALYs. Whether a therapy is cost-
effective and subsequently may be eligible to be included in the Dutch Reimbursement System
depends on how much society is willing to pay for a life year gained in perfect health. Infor-
mally, a ceiling ratio of €20,000–80,000 per QALY has been suggested in the Netherlands in
this respect [33]. Notably, €20,000.00 per QALY can be conceived as maximally strict and very
conservative in our analysis. Base case, sensitivity and scenario analyses followed a cohort of
1,000 patients diagnosed with DVT to calculate the effects and costs of VKAs and dabigatran,
respectively, and corresponding ICERs.
Sensitivity & scenario analyses
Univariate sensitivity analyses were conducted in order to inspect the effects of uncertainty in
key input parameters and assumptions on the ICER, incremental costs and incremental effects
of the base case analysis. Furthermore, to incorporate the uncertainty around all base case
parameters simultaneously in the cost-effectiveness analysis a probabilistic sensitivity analysis
(PSA) was performed. Univariate sensitivity analysis was conducted by changing the parame-
ters to lower and upper bound values corresponding to 95%- confidence limits from the distri-
butions used in the PSA. Notably, beta distributions for probabilities and utilities and gamma
distribution for costs were used in the PSA [34]. PSA was performed by taking a random sam-
ple from the assumed input parameter distributions, calculating QALYs, costs and ICERs in
1,000 replications. Results from univariate sensitivity analyses were presented diagrammati-
cally in the form of tornado diagrams, and results from the PSA were plotted on a CE plane
and transformed into CE-acceptability curves (CEACs).
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Lastly, several scenario analyses were conducted in order to investigate the impact of differ-
ent factors on the outcome. The first scenario analysis reflected the analysis from the more lim-
ited healthcare perspective, whereby production losses and out-of-pocket expenses like travel
and parking costs were excluded. Scenario 2 reflected half of production losses in the base case
assumed. Furthermore, a third scenario assumed that the treatment period of patients diag-
nosed with DVT is exactly that found in our observational data for those patients starting and
ending treatment in the year of observation (2013) as compared to the 180 days from literature
and summaries of product characteristics (SCPs). Scenario 4 calculated the ICER taking only
clinically relevant non-major bleedings and minor bleedings into account, as only these were
found statistically significantly differing in the pooled analysis. Lastly, scenario 5 calculated the
ICER for a treatment period of 90 days to reflect cost-effectiveness for the subgroup with rela-
tively short duration of anticoagulation.
Results
Resource utilization
Resource utilization associated with the use of VKAs in The Netherlands, as well as the INR
monitoring costs related to the resource utilization are presented in Table 1 for the base case
and selected scenarios with differentiating treatment periods. Table 1 shows that the total
mean amount of INR measurements was 12.3 (95% CI 11.3, 13.3), 8.1 (95% CI 7.0, 9.2) mea-
sured at the thrombotic service and 4.2 (95% CI 3.5, 4.9) measured at home. Reflecting the
most conservative duration of treatment in scenario 3, the mean duration of anticoagulation
therapy was observed to consist of 143 days, with indeed sizeable subgroups of patients clus-
tered around 180 days and 90 days. During these mean 143 days there was a total mean amount
of 15.7 (95% CI 14.4, 17.0) INR measurements (12.0 (95% CI 9.9, 14.1) were measured at the
thrombotic service and 3.7 (95% CI 2.8, 4.6) were measured at home). The percentage of INR
measurements sampled at the thrombotic service was 66% versus 76%, in the base case and sce-
nario 3, respectively. The INR monitoring costs for the base case analysis and scenario 3 are
€138 and €168, respectively.
Table 1. Resource utilization and costs of INRmonitoring.
Base case Scenario 3
Total number of patients 189 46
Mean age 65 (± 16) 56 (± 18)
Mean follow up time (days) 220 143
Treatment period (days) 180 143
INR measurements 12.3 (± 6.7) 15.7 (± 4.5)
Thrombotic service 8.1 (± 8.0) 12.0 (± 7.1)
Home 4.2 (± 5.0) 3.7 (± 3.0)
Dose-adjustments 2.9 (± 4.4) 5.5 (± 3.6)
INR monitoring costs (euros) 138 (α = 3.52, β = 39.17) 168 (α = 52.48, β = 10.25)
The total amount of INR measurements, number of times blood sampling for the measurements was at the
thrombotic service, number of times of which blood sampling for the measurements was at home and
number of times a dose-adjustment was needed. Means ± standard deviation are shown. The INR
monitoring costs follow a gamma distribution and are presented as mean values with shape (α) and rate (β)
parameters given in the parenthesis. Base case included all patients treated in the year 2013 with VKAs for
the indication of DVT at the thrombotic service from Deventer Hospital. Scenario 3 included only patients
who started and stopped treatment in the year 2013. Mean treatment period of these patients was 143
days.
INR, international normalized ratio.
doi:10.1371/journal.pone.0135054.t001
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Cost-effectiveness analysis
For a cohort of 1,000 patients, the total number of events associated with the use of VKAs and
dabigatran, as well as the related costs are presented in Table 2. In the base case analysis, dabi-
gatran treatment is associated with an additional QALY of 41.0 (95% uncertainty interval (UI)
-18, 97) compared to VKA treatment. Furthermore, VKA treatment involved with additional
costs compared to dabigatran, related to INR monitoring costs, travelling costs and costs due
to productivity loss. The overall anticoagulant treatment costs were higher for VKA compared
to dabigatran (€591,400 versus €572,400), i.e. cost savings of €18,900 (95% UI €-95,832,
€151,162) were estimated in the base case analysis (Table 3).
Table 2. Events and costs (€, 2013).
VKA Dabigatran
Number of events Costs (€) Number of events Costs (€)
Efﬁcacy
Symptomatic (recurrent) DVT1,2 16.6 26,000 12.5 19,500
Symptomatic (recurrent) non-fatal PE1,2 4.6 22,800 10.3 51,300
Safety
Major bleeding*3 18,9 94,000 15.7 78,000
Non-major or CRNM bleeding3 79.14 7,900 55.71 5,590
Minor bleeding3 193.64 5,000 156.61 4,070
Other costs
Costs of anticoagulants - 14,800 - 414,000
Costs of INR monitoring - 137,500 - -
Travel costs - 78,500 - -
Costs due to productivity loss - 205,000 - -
Total costs
Societal perspective5 - 591,400 - 572,500
Healthcare perspective - 308,000 - 572,500
Total number of events of symptomatic (recurrent) DVT, symptomatic (recurrent) non-fatal PE, bleeding complications and related costs from societal
perspective within a hypothetical patient population of 1,000 subjects receiving dabigatran and VKA for 180 days (base case analysis).
VKA: vitamin-K antagonist; VTE: venous thromboembolism; DVT: deep venous thrombosis; PE: pulmonary embolism: CRNM: clinically relevant non-
major; INR, international normalized ratio.
1Until the end of the post-treatment period
2First occurrence of primary efﬁcacy endpoint
3During double-dummy period
4Statistically signiﬁcant differences between VKA and dabigatran
5Productivity losses by those 50% of the patients being 64 years-of-age and younger.
doi:10.1371/journal.pone.0135054.t002
Table 3. Incremental costs, QALYs and ICER for patients with DVT receiving 180 days anticoagulation therapy from the societal perspective (base
case analysis) for a cohort of 1000 patients.
Treatment Costs (€) QALYs Δ Cost Δ QALY ICER (€/QALY)
VKA € 591,400 5,351 €-18,900 41.0 Cost saving
Dabigatran € 572,400 5,392
QALY: quality adjusted life year; DVT: deep venous thrombosis; ICER: incremental cost-effectiveness ratio; VKA: vitamin-K antagonist.
doi:10.1371/journal.pone.0135054.t003
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Sensitivity analysis
The results of univariate sensitivity analyses for the top 15 parameters by the order of influence
they have to the ICER, incremental costs and effects are presented in the form of tornado dia-
grams (Figs 2–4). The uncertainty around the level of utility associated with INR monitoring,
and with dabigatran use, price of INR monitoring, the price of dabigatran, probabilities of
major bleeding and nonfatal PE with dabigatran and, the costs due to productivity loss showed
the highest impact on uncertainty in the estimated ICERs, incremental costs and effects.
Results from the PSA were plotted in the cost-effectiveness plane (Fig 5) and transformed into
a CEAC. The CEAC of the base case analysis shows that dabigatran is a cost-effective alterna-
tive compared to VKA at a willingness-to-pay threshold of €20,000/QALY in 99% of the simu-
lations and cost saving in 74% of simulations (Fig 6).
Scenario analyses
The impact of different factors on the ICER was further investigated through scenario analyses
(Table 4). From the healthcare perspective, dabigatran is associated with additional QALYs of
41.0 and additional costs of €264,400 compared to VKA. This results in a potentially cost-effec-
tive treatment of dabigatran compared to VKA with an ICER at €6,450 per QALY gained (sce-
nario 1). Taking only half of production losses into account results in additional costs of
Fig 2. Tornado diagram illustrating the impact on the ICER from sensitivity analyses for dabigatran vs. vitamin-K antagonists. Light grey bars
denote influence of the high value of the 95% confidence interval range and dark grey bars denote influence of the low value for parameters investigated. The
solid vertical line represents the base case incremental costs per QALY for dabigatran compared to VKA. Horizontal bars indicate the range of incremental
costs per QALY obtained by setting each variable to the values shown while holding all other values constant. ICER, incremental cost-effectiveness ratio;
INR, international normalized ratio; PE, pulmonary embolism; rDVT, recurrent deep vein thrombosis; VKA, vitamin K antagonist; CRNM, clinically relevant
non-major.
doi:10.1371/journal.pone.0135054.g002
Pharmacoeconomics of Dabigatran vs. Vitamin-K Antagonists in DVT
PLOSONE | DOI:10.1371/journal.pone.0135054 August 4, 2015 8 / 15
€83,600 for dabigatran compared to VKA. Dabigatran may be considered cost-effective at
€2,038per QALY gained (scenario 2). For the conservative DVT treatment duration of 143
days (scenario 3), cost savings remained. When only taking the statistically significant differ-
ences into account during 180 days anticoagulant therapy from the societal perspective (sce-
nario 4) results in marginal additional QALYs and still slight cost savings for dabigatran
compared to VKA. Finally, for the DVT treatment duration of 90 days (scenario 5), cost sav-
ings are shown.
Discussion
Dabigatran compared to VKA for the treatment of DVT was estimated a cost-saving alterna-
tive with €18,900 saved and an additional 41.0 QALYs gained in a cohort of 1,000 DVT
patients in our study’s base case analysis from the societal perspective. The economic benefits
observed with dabigatran treatment correspond with a generally better safety profile (i.e. less
non-major or CRNM and minor bleeding events), a lower number of recurrent DVT events
and their associated costs compared to VKA, but also an absence of productivity loss costs
associated with INR monitoring. QALYs gain with dabigatran compared to VKA can be largely
Fig 3. Tornado diagram illustrating the impact on the incremental costs from sensitivity analyses for dabigatran vs. vitamin-K antagonists. Light
grey bars denote influence of the high value of the 95% confidence interval range and dark grey bars denote influence of the low value for parameters
investigated. The solid vertical line represents the base case incremental costs for dabigatran compared to VKA. Horizontal bars indicate the range of
incremental costs obtained by setting each variable to the values shown while holding all other values constant. INR, international normalized ratio; PE,
pulmonary embolism; rDVT, recurrent deep vein thrombosis; VKA, vitamin K antagonist; CRNM, clinically relevant non-major.
doi:10.1371/journal.pone.0135054.g003
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attributed to disutility associated with INR monitoring in treatment with VKA vs. general pop-
ulation level of utility attached to treatment with dabigatran,
Here, cost savings or favorable cost-effectiveness were robust in scenario and sensitivity
analyses. The base case ICER was found to be below the Dutch informal threshold of €20,000/
QALY in 99% of PSA simulations. Yet, comparing dabigatran treatment with VKA from the
healthcare perspective resulted in the highest ICER found in our study at €6,450/QALY, due to
the productivity loss costs and traveling costs which were excluded. In this situation, dabiga-
tran is still cost-effective considering the informal Dutch threshold of €20,000/QALY. Compar-
ing 143 days (average from real-life data) of dabigatran treatment with VKA from the societal
perspective resulted in higher cost savings compared to the base case 180 days of treatment.
Fig 4. Tornado diagram illustrating the impact on the incremental effects from sensitivity analyses for dabigatran vs. vitamin-K antagonists. Light
grey bars denote influence of the high value of the 95% confidence interval range and dark grey bars denote influence of the low value for parameters
investigated. The solid vertical line represents the base case incremental QALYs for dabigatran compared to VKA. Horizontal bars indicate the range of
incremental QALYs obtained by setting each variable to the values shown while holding all other values constant. INR, international normalized ratio; PE,
pulmonary embolism; rDVT, recurrent deep vein thrombosis; VKA, vitamin K antagonist; CRNM, clinically relevant non-major.
doi:10.1371/journal.pone.0135054.g004
Fig 5. Cost-effectiveness plane in the base case analysis. The graph shows the results of the probabilistic
sensitivity analysis of dabigatran treatment compared to VKA treatment in DVT over a period of 180 days
from the societal perspective. Points below the diagonal line represent simulations in which dabigatran was a
cost-effective alternative at a threshold of €20,000/QALY, below the x-axis, cost-saving points are shown.
doi:10.1371/journal.pone.0135054.g005
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Despite the cost-savings estimated in our base case compared to VKA treatment, dabigatran
treatment may be associated with some disadvantages. During dabigatran treatment, the con-
tacts with the thrombotic service are assumed to disappear and medication surveillance and
monitoring will be limited. As a result, early detection of an inadequate anticoagulant level
might decrease, while concerns on side-effects and therapeutic benefits may compromise com-
pliance [35]. Still, some studies suggest that INR monitoring during VKA treatment not neces-
sarily improves adherence [36,37]. Yet, caution is warranted in interpreting our results and
confirmation in other settings and locations inside and outside the Netherlands is warranted.
Notably, similar analyses for the other NOACs are relevant as well in this respect to support
findings for the NOACs as a group.
Our cost-effectiveness analysis has several limitations. Firstly, one relates to the time in ther-
apeutic range (TTR). We assumed that the efficacies taken from the pooled trials, which were
based on target INR ranges of 2.0 to 3.0 (TTR in most countries), are applicable to the Nether-
lands (with a target INR range of 2.0 to 3.5). Next, the efficacies of dabigatran and VKAs are
based on pooled trials with a follow-up of 6 months, so that long-term risks of adverse events
Fig 6. Cost-effectiveness acceptability curve in the base case analysis.
doi:10.1371/journal.pone.0135054.g006
Table 4. Incremental costs, QALYs and ICER in various scenarios.
Treatment Costs (€) QALYs Δ Cost Δ QALY ICER (€/QALY)
Scenario 1 VKA €308,000 5,351 €264,400 41.0 €6,450
Dabigatran €572,400 5,392
Scenario 2 VKA €488,800 5,351 €83,600 41.0 €2,038
Dabigatran €572,400 5,392
Scenario 3 VKA €613,100 5,351 €-125,700 41.0 Cost saving
Dabigatran €487,300 5,392
Scenario 4 VKA € 13,000 1,797 €-3,300 0.1 Cost saving
Dabigatran € 9,700 1,797
Scenario 5 VKA € 442,000 5,349 €-7,700 41.0 Cost saving
Dabigatran € 365,000 5,390
Patients diagnosed with DVT receiving 180 days anticoagulation therapy from the healthcare perspective (scenario 1), receiving 180 days anticoagulation
therapy with half of production losses (scenario 2), receiving 143 days anticoagulation therapy from the societal perspective (scenario 3), only taking
statistically signiﬁcant differences into account during 180 days anticoagulant therapy from the societal perspective (scenario 4), and receiving 90 days
anticoagulation therapy from the societal perspective (scenario 5), all for a cohort of 1000 patients.
QALY: quality adjusted life year; DVT: deep venous thrombosis; ICER: incremental cost-effectiveness ratio; VKA: vitamin-K antagonist.
doi:10.1371/journal.pone.0135054.t004
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after the 6 months cannot be established and incorporated in the analysis. Notably, the ‘real
life’ long-term benefits of the use of NOACs still need to be proven. Thirdly, in the model, no
difference in the initial treatment with LMWHs was assumed for the respective analyses of
VKAs and dabigatran. From the thrombotic service of Deventer Hospital it could be identified
that the mean treatment period of parenteral anticoagulation was 12.7 days with a mean of 4
INR measurements in combination with VKA in contrast to dabigatran which has a mean
treatment period of down to 5 days of parenteral anticoagulation [15]. Also, VKAs have a 10
times higher risk of drug and food interactions compared to NOACs. Therefore, there might
be patients having to switch from VKA to the more expensive NOACs, which was not included
in the model [38]. Ergo, motivations for both under- and over-estimation of ICERs exist.
Finally, we mention that between the Dutch government and the manufacturer a price-volume
agreement exists in which by increasing volume of dabigatran sales the price reduces. This
means that potentially cost savings may increase and/or ICERs may improve further due to
this agreement.
Furthermore, recent insights into the development and approval of dabigatran have raised
questions about the safety and effectiveness of dabigatran without monitoring and dose adjust-
ment [39]. This has led to a discussion about whether patients taking dabigatran should not
also need INR monitoring and plasma-level testing to reduce the risk of bleeding or clotting
and ensure maximum benefit from the drug [40,41]. Obviously, this will influence our cost-
effectiveness analysis, where the absence of monitoring is a crucial part of the model. Still, all
pharmacoeconomic models for dabigatran so far have this absence of monitoring as core build-
ing block in the analysis, inclusive a recent analysis for NICE [42]. This analysis in the United
Kingdom shows an ICER of £18,200/QALY, still cost-effective according to British norms. The
difference with our estimates may be explained amongst others by differences in country-spe-
cific costs and the third-party payer perspective taken, excluding productivity loss and traveling
costs [42]. Finally, we note that our analysis is specific for DVT; whereas other studies, inclu-
sive the NICE-analysis, take the composite of VTE.
Our model has generalities as well as specificities. We did not subdivide the resource utiliza-
tion of patients treated with acenocoumarol compared to patients treated with phenprocou-
mon. Patients on phenprocoumon have more often INR values in the TTR and require less
intensive resource utilization compared to patients on acenocoumarol. This is particularly rele-
vant for longtime treatment as it takes a relatively long time before patients reach the optimal
INR value of 2.0 to 3.5 on phenprocoumon [8]. Also, before calculating the resource utilization
of patients diagnosed with DVT from the Deventer Hospital, patients on self-measurement
were excluded. These patients were scarce in Deventer. Including large numbers of these
patients though would result in increased cost savings for dabigatran compared to VKA
because of the high costs of self-measurement. Finally, we have focused on DVT only—exclud-
ing initial PE–to be specific. Further work should be directed to a similar analysis for initial PE,
inclusive real-life data gathering. Notably, our results are conditional on the assumptions made
as well as the specific data gathered in the Deventer Hospital. The transformation of our results
to other settings should be considered with great care as INR monitoring is organised quite dif-
ferently across countries.
We conclude that we have designed the first study using real-world observational data of
this specific kind in the Netherlands. These data appeared highly useful in our cost-effective-
ness analysis. Cost savings appeared in the base case, univariate sensitivity and various scenario
analyses. In scenarios lacking cost savings, dabigatran was estimated highly cost-effective. The
favorable pharmacoeconomic profile was robust in probabilistic sensitivity analysis. Confirma-
tion of our findings in other settings, localities and for other NOACs is warranted to support
our study outcomes.
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